141 reports of this reaction
1.3% of all EPIRUBICIN HYDROCHLORIDE reports
#20 most reported adverse reaction
NEOPLASM PROGRESSION is the #20 most commonly reported adverse reaction for EPIRUBICIN HYDROCHLORIDE, manufactured by Pharmacia & Upjohn Company LLC. There are 141 FDA adverse event reports linking EPIRUBICIN HYDROCHLORIDE to NEOPLASM PROGRESSION. This represents approximately 1.3% of all 10,973 adverse event reports for this drug.
Patients taking EPIRUBICIN HYDROCHLORIDE who experience neoplasm progression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEOPLASM PROGRESSION is a less commonly reported adverse event for EPIRUBICIN HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to neoplasm progression, the following adverse reactions have been reported for EPIRUBICIN HYDROCHLORIDE:
The following drugs have also been linked to neoplasm progression in FDA adverse event reports:
NEOPLASM PROGRESSION has been reported as an adverse event in 141 FDA reports for EPIRUBICIN HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEOPLASM PROGRESSION accounts for approximately 1.3% of all adverse event reports for EPIRUBICIN HYDROCHLORIDE, making it a notable side effect.
If you experience neoplasm progression while taking EPIRUBICIN HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.